Stanley Laman Group Ltd. Has $3.61 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Stanley Laman Group Ltd. decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 32,659 shares of the company's stock after selling 9,499 shares during the period. Stanley Laman Group Ltd.'s holdings in Neurocrine Biosciences were worth $3,612,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Golden State Wealth Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter valued at approximately $25,000. Huntington National Bank grew its stake in Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after buying an additional 97 shares during the last quarter. GeoWealth Management LLC raised its holdings in Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after acquiring an additional 102 shares during the period. Lindbrook Capital LLC lifted its position in Neurocrine Biosciences by 53.5% during the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company's stock worth $51,000 after acquiring an additional 130 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in Neurocrine Biosciences by 404.9% during the 1st quarter. Versant Capital Management Inc now owns 409 shares of the company's stock worth $45,000 after acquiring an additional 328 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 9,613 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total value of $1,157,212.94. Following the transaction, the director now owns 514,596 shares of the company's stock, valued at approximately $61,947,066.48. This trade represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William H. Rastetter sold 30,000 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at $4,131,508.20. This represents a 44.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on NBIX shares. Morgan Stanley reiterated an "overweight" rating and issued a $150.00 price objective (down from $185.00) on shares of Neurocrine Biosciences in a research note on Friday, March 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $145.00 price target on shares of Neurocrine Biosciences in a research report on Monday, June 2nd. Wall Street Zen cut Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Thursday, March 20th. Guggenheim boosted their target price on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Finally, BMO Capital Markets upped their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the company a "market perform" rating in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $162.00.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded down $0.62 on Friday, reaching $124.39. The company's stock had a trading volume of 775,176 shares, compared to its average volume of 1,145,538. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.98. The company has a market cap of $12.31 billion, a price-to-earnings ratio of 37.81, a PEG ratio of 0.77 and a beta of 0.24. The business's fifty day moving average price is $113.13 and its 200 day moving average price is $121.91.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). The company had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The company's revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.20 EPS. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Neurocrine Biosciences announced that its Board of Directors has approved a share repurchase plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.